Zika Test from Quest Diagnostics Authorized by the FDA for Emergency Use
/PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it has received a U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the Zika Virus RNA Qualitative Real-Time RT-PCR test (Zika RT-PCR test). The test was developed by the reference laboratory business of Quest’s Focus Diagnostics, Inc., subsidiary. The proprietary molecular test is intended for the qualitative detection of RNA from the Zika virus in human serum specimens from certain individuals. read more
Possible substitute for antibiotics to treat dangerous infections
Infections continue to threaten human health. With remarkable genetic flexibility, pathogenic organisms outsmart available therapies. Fortunately, microbial versatility is matched by the host immune system, which evolves in dialogue with the microbes. Therapies that enhance the beneficial effects of the immune response represent a promising, but under-explored, therapeutic alternative to antibiotics. read more
OV acquires three DRP’s for potential new drug candidates
Oncology Venture Sweden AB (OV:ST) announces the acquisition of three new DRP’s from Medical Prognosis Institute for three new selected, undisclosed anti-cancer drug candidates. OV have now secured a total of ten DRP’s. Three of these are the DRP’s for Irofulven, LiPlaCis and APO010. Using the DRP™ platform, OV intends to enhance the chances of achieving authority approval on its drugs in the pipeline read more
New NCCN Resources for Non-Hodgkin’s Lymphomas Empower Patients to Make Informed Treatment Decisions
FORT WASHINGTON, PA —It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin’s Lymphomas (NHL) in 2016  . The sixth leading cancer diagnosis in U.S. men and women  , NHL has more than 30 sub-types, each featuring unique treatment choices and challenges.  read more
AbbVie to Expand Oncology Presence Through Acquisition of Stemcentrx and its Novel, Late-Stage Rova-T Compound for Small Cell Lung Cancer
/PRNewswire/ — AbbVie (NYSE:ABBV), a global biopharmaceutical company, announced that it will acquire Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T) currently in registrational trials for small cell lung cancer (SCLC). Rova-T is a novel biomarker-specific therapy that is derived from cancer stem cells and targets delta-like protein 3 (DLL3) that is expressed in more than 80 percent of SCLC patient tumors and is not present in healthy tissue. Registrational trials for third-line small cell lung cancer are expected to complete enrollment by the end of 2016. read more
Medtronic VenaSeal Closure System Demonstrates Long-Term Durability and Improved Quality of Life in Patients with Venous Reflux Disease
This week at the 2016 Charing Cross Symposium in London and the International Vein Congress in Miami, Medtronic plc (NYSE: MDT) unveiled clinical data for the VenaSeal(TM) closure system demonstrating consistent long-term durability and improved quality of life in patients with venous reflux disease. The new data presented included two-year outcomes from the VeClose pivotal clinical study, with two additional subanalyses evaluating quality of life and physician ease-of-use; and three-year results from the European Sapheon Closure System Observational ProspectivE (eSCOPE) study. read more
Late-Breaking Clinical Trial Session Features Subcutaneous Implantable Defibrillator Data
/PRNewswire/ — Boston Scientific (NYSE: BSX) today announced key data, including one late-breaking clinical trial, that will be featured at the 37th Annual Scientific Sessions of the Heart Rhythm Society (HRS) in San Francisco on May 4-7.
Data from the EFFORTLESS study, the first large-scale, multi-national, post-market analysis of safety and efficacy of the subcutaneous implantable defibrillator (S-ICD), will be featured at the late-breaking clinical trial session on Friday, May 6. Other presentations and abstracts of interest include: read more
Precise Biometrics Signs License Agreement with IDEX
Regulatory News: Precise Biometrics (STO:PREC), the leader in fingerprint software, has entered an agreement with IDEX for licensing of Precise Biometrics’ portfolio of algorithm solutions for fingerprint recognition. The license agreement will generate royalty revenue based on sales of fingerprint sensors from IDEX that includes Precise Biometrics’ algorithm solutions. Royalty revenues are volume dependent and cannot be forecasted at this point. The agreement includes a limited initial fixed fee for the right to integrate and use Precise Biometrics’ software, which will be recognized starting from the second quarter 2016.
Sanofi US Collaborates with Duke University and Massachusetts General Hospital on Big Data and Type 2 Diabetes
PRNewswire/ — Sanofi US announced today collaborations with the Duke Clinical Research Institute (DCRI) and, separately, with the Center for Assessment Technology and Continuous Health (CATCH) at Massachusetts General Hospital. The collaborations are designed to create new tools that will help predict how people living with type 2 diabetes adhere to their medication. read more
Wenzel Spine Announces Commercial Launch of the VariLift®-LX
AUSTIN, Texas–(BUSINESS WIRE)–Wenzel Spine, Inc., a pioneer medical device company focused on providing minimally invasive, expandable stand-alone alternatives to traditional spinal fusion, announced today the full commercial availability of the VariLift®-LX System throughout the U.S. , visit www.wenzelspine.com.